new glp 1 retatrutide 🎙️ EPISODE: Retatrutide—The Triple Agonist *Not licensed* Will this replace the current GLP-1 in the market., This triple receptor agonist (GIP/GLP-1/glucagon) is showing unprecedented results in Retatrutide Weight Loss | GLP-1,

In: Amir Ashraf S, Adnan M, eds

Notably, individuals in Tyde Wellness have reported an average body weight reduction of 15% after 68 weeks, underscoring the efficacy of these treatments

Yes, behavior change plays a crucial role in long-term success , especially with GLP-1 medications

Retatrutide is not approved by the Medicines and Healthcare products Regulatory Agency (MHRA) or the European Medicines Agency (EMA) and remains under clinical investigation

You should contact your GP if you experience: Absence of periods for three consecutive cycles (amenorrhoea) if you previously had regular menstruation Unusually heavy bleeding (soaking through a pad or tampon every hour for several consecutive hours) or passing large clots Bleeding between periods or after intercourse, which requires investigation regardless of medication use Severe pelvic pain that differs from typical menstrual cramping Symptoms of anaemia including persistent fatigue, breathlessness, palpitations, or pallor Seek urgent medical help via NHS 111 or A&E for very heavy bleeding with dizziness or fainting, or severe abdominal pain that could indicate complications such as pancreatitis

Pancreatitis was not reported in the RCTs (5261)